Cannabis Stocks Rally Toward Best Weekly Performance in 2024
Multi-state operators and Canadian LPs surge as sector momentum builds on regulatory optimism and improving fundamentals across key markets.
Cannabis equities are experiencing their strongest weekly performance of 2024, with major multi-state operators and Canadian licensed producers posting double-digit gains as investor sentiment shifts decisively positive. The AdvisorShares Pure US Cannabis ETF (MSOS) has climbed 12% this week, while the Horizons Marijuana Life Sciences ETF has gained 15%, marking the sector's most robust rally since early 2023.
The surge reflects growing investor confidence in federal rescheduling progress and state-level market maturation. Industry leaders including Curaleaf Holdings, Green Thumb Industries, and Cresco Labs have each posted gains exceeding 18% as institutional money flows back into the space. Canadian operators Canopy Growth and Tilray Brands are up 22% and 19% respectively, benefiting from renewed cross-border expansion optimism.
Fundamental improvements across state markets are driving the rally beyond regulatory speculation. Q3 earnings demonstrated margin expansion for top-tier operators, with several MSOs achieving positive EBITDA growth despite pricing pressures. Florida's recreational ballot measure and potential federal banking reform have created a perfect storm of catalysts that sophisticated investors are positioning for ahead of 2024 election outcomes.
The week's performance represents a stark reversal from the sector's prolonged underperformance, where cannabis stocks had lagged broader markets by over 40% year-to-date. Trading volumes have surged 300% above recent averages, indicating institutional participation rather than retail speculation. Options activity shows heavy call buying in major names, suggesting investors expect momentum to continue through year-end.
This rally could mark an inflection point for cannabis equities, which have traded at severe discounts to traditional consumer goods and pharmaceutical comparables despite generating billions in revenue. With several states preparing adult-use launches in 2024 and federal policy tailwinds building, the sector appears to be breaking out of its multi-year consolidation phase into what could become a sustained bull market.